Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist
- PMID: 6232019
- DOI: 10.1111/j.1365-2265.1984.tb00066.x
Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist
Abstract
Superactive analogues of gonadotrophin releasing hormone and testosterone, when administered together, synergistically inhibit gonadotrophin secretion and spermatogenesis in the rat. In order to determine whether testosterone also enhanced gonadotrophin suppression by GnRH agonist in the human male, two groups of four normal male volunteers first received either 10 or 100 micrograms of a GnRH agonist D(Nal2)6GnRH (GnRH-A) daily for 10 d. After at least a 50 d recovery period, the same subjects received a single injection of 200 mg of testosterone oenanthate (TE) on day 1 in addition to the same dose of GnRH-A daily for 10 d. Serum LH, FSH and testosterone (TS) concentrations were measured daily just prior to the next analogue dose, and on days 1 and 10 at 0, 1, 2, 4, 6, 8, 12, 16 and 24 h after the analogue injection. Daily administration of both 10 and 100 micrograms of GnRH-A alone resulted in an early phase of stimulation followed by progressive decline in LH, FSH and testosterone to levels below baseline by day 10 despite continued administration of GnRH-A. Addition of testosterone to 10 micrograms of GnRH-A resulted in hormonal responses identical to those seen with GnRH-A alone. Combined treatment of testosterone with 100 micrograms of GnRH-A did not blunt the peak LH and FSH responses on day 2, but resulted in significantly lower LH (mean integrated responses: 187 +/- 30 vs. 234 +/- 42 mIU-d/ml) and FSH (mean integrated responses: 20.6 +/- 3.3 vs. 32.8 +/- 4.2 mIU-d/ml) responses from days 3 to 11. By day 11, all subjects receiving combined treatment (GnRH-A 100 micrograms + testosterone oenanthate) had undetectable serum FSH levels. In contrast, serum FSH concentrations on day 11 after treatment with GnRH-A alone were 43.6 +/- 8.9% of control and none of the subjects had values below the limit of detection. Serum testosterone levels in the combined treatment group did not fall below baseline by day 10 in either the 10 (161.4 +/- 48%) or the 100 micrograms GnRH-A groups (104.6 +/- 11.2%), while in the group receiving GnRH-A alone, testosterone levels declined to 45.6 +/- 8.3% and 80 +/- 18.8% with the 10 and 100 micrograms dose respectively. We conclude that addition of a suppressive dose of testosterone to an appropriate dose of GnRN-A significantly enhances gonadotrophin suppression by GnRH-A in the human male.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.J Clin Endocrinol Metab. 1985 May;60(5):998-1003. doi: 10.1210/jcem-60-5-998. J Clin Endocrinol Metab. 1985. PMID: 3920237
-
Hormonal effects of GnRH agonist in the human male: an approach to male contraception using combined androgen and GnRH agonist treatment.J Steroid Biochem. 1985 Nov;23(5B):855-61. doi: 10.1016/s0022-4731(85)80027-3. J Steroid Biochem. 1985. PMID: 2934582
-
The stimulatory and down-regulatory effects of a gonadotropin-releasing hormone agonist in man.J Clin Endocrinol Metab. 1984 Jun;58(6):1084-8. doi: 10.1210/jcem-58-6-1084. J Clin Endocrinol Metab. 1984. PMID: 6233295
-
Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.J Clin Endocrinol Metab. 1995 Aug;80(8):2394-403. doi: 10.1210/jcem.80.8.7543113. J Clin Endocrinol Metab. 1995. PMID: 7543113 Clinical Trial.
-
Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.J Clin Endocrinol Metab. 1987 Sep;65(3):568-74. doi: 10.1210/jcem-65-3-568. J Clin Endocrinol Metab. 1987. PMID: 3114307
Cited by
-
Continuing the search for a hormonal male contraceptive.Best Pract Res Clin Obstet Gynaecol. 2020 Jul;66:83-94. doi: 10.1016/j.bpobgyn.2020.02.003. Epub 2020 Feb 19. Best Pract Res Clin Obstet Gynaecol. 2020. PMID: 32197832 Free PMC article. Review.
-
Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.Drugs. 1990 Apr;39(4):523-51. doi: 10.2165/00003495-199039040-00005. Drugs. 1990. PMID: 2140979 Review.
-
Contraception across transgender.Int J Impot Res. 2020 Nov;33(7):710-719. doi: 10.1038/s41443-021-00412-z. Epub 2021 Feb 8. Int J Impot Res. 2020. PMID: 33558672 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources